Stereotactic MR-guided on-table adaptive radiation therapy (SMART) for borderline resectable and locally advanced pancreatic cancer: A multi-center, open-label phase 2 study

• Published in: Radiotherapy and oncology Vol. 191; p. 110064
• Main Authors: Chuong, Michael D., Lee, Percy, Low, Daniel A., Kim, Joshua, Mittauer, Kathryn E., Bassetti, Michael F., Glide-Hurst, Carri K., Raldow, Ann C., Yang, Yingli, Portelance, Lorraine, Padgett, Kyle R., Zaki, Bassem, Zhang, Rongxiao, Kim, Hyun, Henke, Lauren E., Price, Alex T., Mancias, Joseph D., Williams, Christopher L., Ng, John, Pennell, Ryan, Raphael Pfeffer, M., Levin, Daphne, Mueller, Adam C., Mooney, Karen E., Kelly, Patrick, Shah, Amish P., Boldrini, Luca, Placidi, Lorenzo, Fuss, Martin, Jitendra Parikh, Parag
• Format: Journal Article
• Language: English
• Published: Ireland Elsevier B.V 01.02.2024
• Subjects: Adenocarcinoma; Induction chemotherapy; Pancreatic neoplasms; Radiotherapy; Adenocarcinoma; Induction chemotherapy; Radiotherapy; Pancreatic neoplasms
• ISSN: 0167-8140; 1879-0887; 1879-0887
• DOI: 10.1016/j.radonc.2023.110064

•This is the first prospective study of ablative 5-fraction stereotactic magnetic resonance-guided adaptive radiation therapy (SMART) for borderline resectable and locally advanced pancreas cancer.•We previously published that no acute grade ≥ 3 gastrointestinal (GI) toxicity definitely attributed to SMART was observed in any patient.•Long-term outcomes include 2-year overall survival from diagnosis and SMART of 53.6 % and 40.5 %, respectively, and minimal late grade ≥ 3 GI toxicity.•Additional prospective evaluation of this novel ablative strategy compared to chemotherapy alone is warranted. Radiation dose escalation may improve local control (LC) and overall survival (OS) in select pancreatic ductal adenocarcinoma (PDAC) patients. We prospectively evaluated the safety and efficacy of ablative stereotactic magnetic resonance (MR)-guided adaptive radiation therapy (SMART) for borderline resectable (BRPC) and locally advanced pancreas cancer (LAPC). The primary endpoint of acute grade ≥ 3 gastrointestinal (GI) toxicity definitely related to SMART was previously published with median follow-up (FU) 8.8 months from SMART. We now present more mature outcomes including OS and late toxicity. This prospective, multi-center, single-arm open-label phase 2 trial (NCT03621644) enrolled 136 patients (LAPC 56.6 %; BRPC 43.4 %) after ≥ 3 months of any chemotherapy without distant progression and CA19-9 ≤ 500 U/mL. SMART was delivered on a 0.35 T MR-guided system prescribed to 50 Gy in 5 fractions (biologically effective dose10 [BED10] = 100 Gy). Elective coverage was optional. Surgery and chemotherapy were permitted after SMART. Mean age was 65.7 years (range, 36–85), induction FOLFIRINOX was common (81.7 %), most received elective coverage (57.4 %), and 34.6 % had surgery after SMART. Median FU was 22.9 months from diagnosis and 14.2 months from SMART, respectively. 2-year OS from diagnosis and SMART were 53.6 % and 40.5 %, respectively. Late grade ≥ 3 toxicity definitely, probably, or possibly attributed to SMART were observed in 0 %, 4.6 %, and 11.5 % patients, respectively. Long-term outcomes from the phase 2 SMART trial demonstrate encouraging OS and limited severe toxicity. Additional prospective evaluation of this novel strategy is warranted.